Novel Treatment Strategies for Patients With Relapsed Classical Hodgkin Lymphoma

Blood Reviews - United States
doi 10.1016/j.blre.2010.08.003
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Novel Therapeutic Agents for Relapsed Classical Hodgkin Lymphoma

British Journal of Haematology
Hematology
2018English

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group

Klinicka Onkologie
Oncology
2016English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience

Acta Haematologica Polonica
OncologyHematology
2018English

Leucocyte and Eosinophil Counts Predict Progression-Free Survival in Relapsed or Refractory Classical Hodgkin Lymphoma Patients Treated With PD1 Inhibition

British Journal of Haematology
Hematology
2017English

Lymphocyte-Rich Classical Hodgkin Lymphoma

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2018English

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

British Journal of Haematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy